{
  "schemaVersion": 2,
  "eyebrow": "Maternal-Fetal Medicine",
  "title": "Eclampsia",
  "summary": "Eclampsia is a seizure emergency in pregnancy or postpartum. Stabilize airway and circulation, terminate convulsions with magnesium sulfate, urgently control sustained severe hypertension, evaluate competing neurologic diagnoses, and plan delivery after maternal stabilization rather than during uncontrolled seizure activity.",
  "seoDescription": "Eclampsia diagnosis and emergency management: magnesium sulfate, severe hypertension treatment, maternal stabilization, delivery planning, and postpartum evaluation.",
  "clinicalQuestion": "How should clinicians rapidly stabilize, treat, evaluate, and plan delivery for eclampsia during pregnancy or postpartum?",
  "specialty": "Obstetrics and Maternal-Fetal Medicine",
  "audience": "U.S. physicians and medical trainees",
  "tags": [
    "eclampsia",
    "preeclampsia with severe features",
    "magnesium sulfate",
    "severe hypertension in pregnancy",
    "postpartum eclampsia"
  ],
  "keyTakeaways": [
    "Treat a new generalized tonic-clonic, focal, or multifocal seizure during pregnancy or postpartum as eclampsia after immediate stabilization and parallel exclusion of alternative causes; hypertension and proteinuria may be absent before seizure onset. [20]",
    "Magnesium sulfate is first-line for seizure control and prevention of recurrence; the FDA label identifies immediate anticonvulsant onset and effective serum concentrations of 2.5–7.5 mEq/L. [3]",
    "Sustained severe hypertension requires prompt treatment with pregnancy-compatible agents; IV labetalol, IV hydralazine, or oral nifedipine are recommended first-line options in critical care guidance. [23]",
    "Delivery is definitive treatment for the underlying disorder, but maternal stabilization, seizure control, and blood pressure treatment take priority before delivery planning. [5][13]",
    "Do not stop surveillance after delivery: eclampsia may occur postpartum, with highest risk in the first postpartum week. [20]"
  ],
  "sections": [
    {
      "id": "recognition-and-diagnosis",
      "eyebrow": "Recognition",
      "heading": "Recognize eclampsia despite incomplete preeclampsia findings",
      "intro": "Diagnostic delay is most consequential when seizure is attributed to a nonobstetric cause without treating pregnancy-related disease.",
      "paragraphs": [
        "Eclampsia is new-onset generalized tonic-clonic, focal, or multifocal seizure in a patient with a hypertensive disorder of pregnancy when another neurologic cause is not more likely. It can occur before, during, or after delivery. Although it commonly follows preeclampsia, seizures may occur without antecedent severe hypertension or proteinuria; absence of either finding must not delay magnesium sulfate or blood pressure assessment. [20]",
        "Symptoms preceding seizure may include severe headache, visual disturbance, altered mental status, or epigastric/right upper quadrant pain, but none reliably excludes sudden eclampsia. Pregnancy-associated seizures before 20 weeks, more than 48 hours postpartum, with focal deficits, recurrent seizures, or prolonged coma warrant especially active evaluation for alternate neurologic diagnoses. [20]"
      ],
      "bullets": [
        "Measure blood pressure immediately and repeat promptly; severe-range hypertension is systolic blood pressure at least 160 mm Hg or diastolic blood pressure at least 110 mm Hg. [20][24]",
        "Obtain CBC with platelet count, serum creatinine/electrolytes, hepatic panel, and urine protein assessment while resuscitation proceeds; proteinuria is not required for preeclampsia/eclampsia. [20][24]",
        "Use chest imaging when pulmonary edema is suspected and obstetric ultrasound for fetal assessment after maternal stabilization. [20]",
        "Obtain neuroimaging for focal neurologic signs, recurrent seizures, prolonged coma, persistent headache or visual symptoms despite hypertension treatment, or atypical timing; evaluate for stroke, posterior reversible encephalopathy syndrome, cerebral venous thrombosis, and other competing diagnoses. [20][21]"
      ],
      "subsections": [],
      "table": {
        "caption": "Findings that support eclampsia or demand an expanded differential diagnosis. [20][24]",
        "columns": [
          "Clinical finding",
          "Immediate implication"
        ],
        "rows": [
          [
            "New seizure during pregnancy or early postpartum",
            "Initiate eclampsia management while evaluating other causes. [20]"
          ],
          [
            "Severe headache, visual symptoms, altered mental status, epigastric/right upper quadrant pain",
            "Assess for preeclampsia severe features and neurologic or hepatic complications. [20][24]"
          ],
          [
            "Focal deficit, recurrent seizure, prolonged unconsciousness, seizure before 20 weeks or >48 hours postpartum",
            "Add urgent neurologic evaluation and neuroimaging as clinically indicated. [20]"
          ],
          [
            "Dyspnea, rales, hypoxemia, or clinical volume overload",
            "Assess for pulmonary edema and cardiac dysfunction; avoid unnecessary volume loading. [13][20]"
          ]
        ]
      }
    },
    {
      "id": "emergency-management",
      "eyebrow": "Emergency care",
      "heading": "Stabilize the mother and stop the seizure first",
      "intro": "Management is simultaneous resuscitation, anticonvulsant therapy, and treatment of severe hypertension.",
      "paragraphs": [
        "During active seizure, protect the patient from injury, position laterally when feasible, maintain oxygenation and airway patency, establish IV access, and assess maternal cardiopulmonary status. Continuous fetal monitoring is appropriate once maternal resuscitation permits, but fetal intervention should not supersede maternal stabilization. Eclampsia is an obstetric emergency requiring coordinated obstetric, anesthesia, and critical care management. [20]",
        "Magnesium sulfate is first-line therapy for eclamptic seizure treatment and recurrence prevention. FDA labeling states that IV anticonvulsant activity is immediate and lasts about 30 minutes; serum magnesium concentrations typically sufficient to control convulsions range from 2.5 to 7.5 mEq/L. [3] The supplied FDA label does not provide a loading or maintenance dose in the available excerpt; use an institutionally approved obstetric magnesium protocol rather than extrapolating from the label. [3]"
      ],
      "bullets": [
        "Keep injectable calcium immediately available during magnesium infusion; discontinue magnesium and reassess serum concentration if clinically significant toxicity develops. [3]",
        "Monitor patellar reflexes, respiratory rate, urine output, and serum magnesium concentration during infusion. Reflexes diminish above 4 mEq/L and may disappear near 10 mEq/L, where respiratory paralysis is a major hazard. [3]",
        "Patients with urine output below 100 mL per 4 hours or progressive creatinine elevation are at increased risk of magnesium toxicity; the label recommends discontinuing infusion when urine output is below this threshold. [3]",
        "Magnesium is contraindicated in known myasthenia gravis because it can precipitate myasthenic crisis. [3]",
        "Avoid coadministration with neuromuscular blockers without close respiratory and train-of-four monitoring; magnesium can potentiate and prolong blockade. [3]",
        "Monitor closely with dihydropyridine calcium-channel blockers because exaggerated hypotension has been reported. [3]"
      ],
      "subsections": [
        {
          "heading": "Control sustained severe hypertension",
          "paragraphs": [
            "In pregnancy-associated hypertensive emergency, rapidly treat sustained blood pressure of at least 160/110 mm Hg. In a critical care setting, NICE identifies labetalol (oral or IV), oral nifedipine, and IV hydralazine as immediate treatment options, with response monitoring for blood pressure reduction and adverse effects. [23] The FDA magnesium label also warns against coadministration with unapproved tocolytics, including terbutaline or nifedipine, because pulmonary edema and hypotension have occurred; this warning concerns tocolytic coadministration and does not replace obstetric severe-hypertension protocols. [3]",
            "Avoid ACE inhibitors, angiotensin receptor blockers, direct renin inhibitors, and nitroprusside during pregnancy-associated hypertensive emergency; NICE identifies these as contraindicated in eclampsia or preeclampsia. [23]"
          ],
          "bullets": []
        }
      ],
      "table": {
        "caption": "Magnesium sulfate safety surveillance during eclampsia treatment. [3]",
        "columns": [
          "Monitor",
          "Concerning finding",
          "Action supported by labeling"
        ],
        "rows": [
          [
            "Respiratory status",
            "Respiratory depression or decreasing rate",
            "Stop infusion for significant toxicity; support ventilation and give injectable calcium salt. [3]"
          ],
          [
            "Deep-tendon reflexes",
            "Diminished reflexes >4 mEq/L; absent reflexes near 10 mEq/L",
            "Reassess for toxicity and serum magnesium concentration. [3]"
          ],
          [
            "Urine output",
            "<100 mL over 4 hours",
            "Discontinue infusion to reduce toxicity risk, especially with rising creatinine. [3]"
          ],
          [
            "Renal function",
            "Severe renal impairment or oliguria",
            "Reduce dosage; magnesium is renally excreted. [3]"
          ]
        ]
      }
    },
    {
      "id": "delivery-and-critical-care",
      "eyebrow": "Definitive care",
      "heading": "Plan delivery after maternal stabilization",
      "intro": "Delivery stops the pregnancy-specific disease process but does not immediately eliminate maternal risk.",
      "paragraphs": [
        "Delivery is the definitive treatment for preeclampsia/eclampsia. In eclampsia, control seizures, stabilize airway and oxygenation, and initiate severe-hypertension treatment before proceeding with delivery planning; the route and timing of delivery depend on maternal stabilization, gestational age, fetal status, and obstetric circumstances. [5][13][20]",
        "NICE advises IV magnesium sulfate for a woman with eclampsia in critical care and recommends selecting mode of birth according to clinical circumstances and the woman’s preference. [23] For preterm planned birth in preeclampsia, provide antenatal corticosteroids and magnesium sulfate when indicated; delivery should not be delayed when there is maternal or fetal deterioration. [23][24]"
      ],
      "bullets": [
        "Escalate to critical care for severe hypertension, severe preeclampsia, or eclampsia when organ dysfunction, respiratory compromise, or intensive monitoring is required. [23]",
        "Limit maintenance fluids in severe preeclampsia to 80 mL/hour unless there are other ongoing losses; avoid routine volume expansion except when IV hydralazine is used antenatally. [23]",
        "Pulmonary edema in preeclampsia is associated with endothelial permeability, cardiac dysfunction, corticosteroid/tocolytic exposure, and iatrogenic volume overload. [13]",
        "Maternal indications for expedited birth include uncontrolled hypertension despite multiple antihypertensive classes, progressive renal/hepatic/hematologic dysfunction, persistent neurologic features or eclampsia, placental abruption, and serious fetal compromise. [23]"
      ],
      "subsections": [],
      "table": {
        "caption": "Delivery decisions in eclampsia and severe preeclampsia are driven by maternal stabilization and evidence of deterioration. [23][24]",
        "columns": [
          "Situation",
          "Clinical priority"
        ],
        "rows": [
          [
            "Active eclamptic seizure",
            "Stabilize airway, stop seizure with magnesium sulfate, assess severe hypertension, then proceed to delivery planning. [20][23]"
          ],
          [
            "Eclampsia or ongoing severe neurologic features",
            "Treat as a critical care indication; delivery is generally indicated after stabilization. [23][24]"
          ],
          [
            "Preterm disease with stable maternal and fetal status",
            "Individualize expectant management in a center capable of maternal-fetal surveillance; give corticosteroids and magnesium when indicated. [23][24]"
          ],
          [
            "Pulmonary edema, abruption, worsening laboratory abnormalities, uncontrolled hypertension, or nonreassuring fetal status",
            "Expedite delivery after maternal stabilization. [23][24]"
          ]
        ]
      }
    },
    {
      "id": "postpartum-care",
      "eyebrow": "Postpartum",
      "heading": "Maintain surveillance after delivery",
      "intro": "Postpartum onset and deterioration are common sources of missed diagnosis.",
      "paragraphs": [
        "Eclampsia can occur postpartum, most often within 48 hours after delivery, with highest risk during the first postpartum week. [20] New-onset postpartum preeclampsia should be considered with hypertension arising 48 hours to 6 weeks after delivery, particularly when severe features are present. [21]",
        "For women with preeclampsia after birth, NICE recommends frequent inpatient blood pressure measurement, symptom assessment for severe headache and epigastric pain at each measurement, and post-discharge monitoring based on antihypertensive treatment status. [23] This surveillance is clinically important because postpartum blood pressure often worsens on days 3 to 7. [21]"
      ],
      "bullets": [
        "Assess for severe headache, visual symptoms, epigastric pain, dyspnea, chest pain, edema, and neurologic change; refractory or thunderclap headache or headache with focal deficits, seizure, visual disturbance, or altered mental status requires evaluation for alternate cerebrovascular diagnoses. [21]",
        "For postpartum preeclampsia without antenatal antihypertensive treatment, NICE recommends starting therapy at blood pressure 150/100 mm Hg or higher. [23]",
        "For sustained severe postpartum hypertension, ACOG-referenced guidance supports rapid-acting therapy with IV labetalol, IV hydralazine, or oral nifedipine within 30–60 minutes. [21]",
        "Breastfeeding is compatible with antihypertensive treatment. NICE recommends enalapril with maternal creatinine and potassium monitoring and advises avoiding ARBs or diuretics where possible during breastfeeding. [23]",
        "At 6–8 weeks postpartum, reassess blood pressure and residual proteinuria; persistent proteinuria warrants later kidney-function review. [23]"
      ],
      "subsections": [
        {
          "heading": "Long-term implications",
          "paragraphs": [
            "A history of hypertensive disorders of pregnancy is associated with later hypertension and cardiovascular disease. NICE recommends counseling regarding smoking avoidance, healthy lifestyle, weight management, and cardiovascular risk reduction. [23] Eclampsia is also associated with increased future preeclampsia risk and low absolute but increased risk of later seizure disorders. [20]"
          ],
          "bullets": []
        }
      ],
      "table": {
        "caption": "Postpartum monitoring actions for preeclampsia. [21][23]",
        "columns": [
          "Time frame",
          "Monitoring and action"
        ],
        "rows": [
          [
            "Inpatient after preeclampsia",
            "Measure blood pressure at least 4 times daily; ask about severe headache and epigastric pain at each assessment. [23]"
          ],
          [
            "Days 3–5 postpartum",
            "Ensure blood pressure assessment because postpartum worsening is common. [21][23]"
          ],
          [
            "After community transfer",
            "Women on antihypertensives require blood pressure assessment every 1–2 days for up to 2 weeks in NICE guidance. [23]"
          ],
          [
            "6–8 weeks postpartum",
            "Medical review and urine dipstick; persistent proteinuria requires further kidney assessment. [23]"
          ]
        ]
      }
    },
    {
      "id": "pathophysiology",
      "eyebrow": "Mechanism",
      "heading": "Link placental disease to maternal neurologic injury",
      "intro": "Mechanism matters because seizures may occur without extreme hypertension.",
      "paragraphs": [
        "The dominant model begins with abnormal trophoblast invasion and incomplete spiral-artery remodeling, producing placental ischemia and release of antiangiogenic factors, particularly soluble fms-like tyrosine kinase-1 and soluble endoglin. These factors disrupt vascular endothelial growth factor and transforming growth factor-β signaling, promoting systemic endothelial dysfunction, vasoconstriction, oxidative stress, and multiorgan injury. [13]",
        "For eclampsia, impaired cerebral autoregulation and blood-brain barrier dysfunction are leading mechanistic explanations. Vasogenic edema and posterior reversible encephalopathy syndrome are common imaging correlates, but eclampsia can occur below severe-range blood pressure, supporting a role for endothelial injury beyond blood pressure alone. [13][20]"
      ],
      "bullets": [
        "Renal glomerular endotheliosis and podocyte injury explain proteinuria and reduced filtration. [13]",
        "Increased systemic vascular resistance and diastolic dysfunction contribute to pulmonary edema risk, particularly with excessive IV fluid administration. [13]",
        "Hepatic microcirculatory injury, platelet activation/consumption, and microangiopathy underlie HELLP-spectrum findings. [13]"
      ],
      "subsections": [],
      "table": {
        "caption": "Mechanistic findings that alter clinical interpretation. [13][20]",
        "columns": [
          "Mechanism",
          "Clinical consequence"
        ],
        "rows": [
          [
            "Endothelial dysfunction from placental antiangiogenic factors",
            "Multisystem involvement can occur without proteinuria. [13]"
          ],
          [
            "Cerebral autoregulatory and blood-brain barrier dysfunction",
            "Seizure, vasogenic edema, and posterior reversible encephalopathy syndrome; image when neurologic course is atypical or persistent. [13][20]"
          ],
          [
            "Renal endothelial and podocyte injury",
            "Proteinuria, creatinine elevation, and magnesium accumulation risk when renal clearance falls. [3][13]"
          ],
          [
            "Elevated afterload with capillary leak and volume shifts",
            "Pulmonary edema risk; use fluids judiciously and assess volume status. [13][23]"
          ]
        ]
      }
    }
  ],
  "faq": [
    {
      "question": "Can eclampsia occur without proteinuria or severe hypertension?",
      "answer": "Yes. Eclampsia may occur without preceding proteinuria or severe hypertension; treat a new seizure in pregnancy or postpartum as eclampsia while evaluating competing neurologic causes. [20]"
    },
    {
      "question": "What is the first-line anticonvulsant for eclampsia?",
      "answer": "IV magnesium sulfate is first-line for seizure treatment and prevention of recurrence. Monitor respiratory status, reflexes, urine output, and magnesium concentration, particularly with renal impairment. [3][20]"
    },
    {
      "question": "When should neuroimaging be obtained in eclampsia?",
      "answer": "Obtain neuroimaging for focal deficits, recurrent seizures, prolonged coma, persistent headache or visual symptoms despite treatment, or atypical onset before 20 weeks or more than 48 hours postpartum. [20][21]"
    },
    {
      "question": "Does delivery occur immediately during an eclamptic seizure?",
      "answer": "No. First stabilize the mother, control seizure activity, and address severe hypertension. Delivery is definitive treatment but should follow maternal stabilization and individualized obstetric assessment. [5][13][20]"
    },
    {
      "question": "How long after delivery can postpartum eclampsia occur?",
      "answer": "Risk is highest in the first postpartum week, although postpartum preeclampsia is considered with new-onset hypertension from 48 hours through 6 weeks after delivery. [20][21]"
    }
  ],
  "references": [
    {
      "number": 1,
      "title": "highlights of prescribing information",
      "detail": "dailymed.nlm.nih.gov",
      "url": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=eaf135b6-e378-4f62-a1e7-db45e23668c7&type=display",
      "authors": "dailymed.nlm.nih.gov",
      "host": "dailymed.nlm.nih.gov"
    },
    {
      "number": 2,
      "title": "These highlights do not include all the information needed to use Irbesartan and Hydrochlorothiazide safely and effectively. See full prescribing information for Irbesartan and Hydrochlorothiazide.\n \n      \nIrbesartan and Hydrochlorothiazide tablets, for oral use\n \nInitial U.S. Approval: 1997",
      "detail": "dailymed.nlm.nih.gov",
      "url": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=89701339-861a-4e54-a3d6-cf84046e54f2&type=display",
      "authors": "dailymed.nlm.nih.gov",
      "host": "dailymed.nlm.nih.gov"
    },
    {
      "number": 3,
      "title": "DailyMed - MAGNESIUM SULFATE IN DEXTROSE- magnesium sulfate heptahydrate injection, solution",
      "detail": "dailymed.nlm.nih.gov",
      "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4876dcd9-5e8f-47ed-af4f-6a4009ccffd1",
      "authors": "dailymed.nlm.nih.gov",
      "host": "dailymed.nlm.nih.gov"
    },
    {
      "number": 4,
      "title": "DailyMed - MAGNESIUM SULFATE IN DEXTROSE- magnesium sulfate injection",
      "detail": "dailymed.nlm.nih.gov",
      "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8da9c33f-e3cd-4026-b034-2b964401b346",
      "authors": "dailymed.nlm.nih.gov",
      "host": "dailymed.nlm.nih.gov"
    },
    {
      "number": 5,
      "title": "Predictive Value of the sFlt-1:PlGF Ratio in Women with ...",
      "detail": "www.nejm.org",
      "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1414838",
      "authors": "www.nejm.org",
      "host": "www.nejm.org"
    },
    {
      "number": 6,
      "title": "Pre-eclampsia - Symptoms, diagnosis and treatment | BMJ Best Practice",
      "detail": "bestpractice.bmj.com",
      "url": "https://bestpractice.bmj.com/topics/en-us/326",
      "authors": "bestpractice.bmj.com",
      "host": "bestpractice.bmj.com"
    },
    {
      "number": 7,
      "title": "Strengthening global pre-eclampsia diagnosis",
      "detail": "www.thelancet.com",
      "url": "https://www.thelancet.com/journals/lanogw/article/PIIS3050-5038(26)00057-9/abstract",
      "authors": "www.thelancet.com",
      "host": "www.thelancet.com"
    },
    {
      "number": 8,
      "title": "Placental growth factor testing to assess women with ...",
      "detail": "www.thelancet.com",
      "url": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)33212-4/fulltext",
      "authors": "www.thelancet.com",
      "host": "www.thelancet.com"
    },
    {
      "number": 9,
      "title": "Treatment for Mild Chronic Hypertension during Pregnancy",
      "detail": "www.nejm.org",
      "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa2201295",
      "authors": "www.nejm.org",
      "host": "www.nejm.org"
    },
    {
      "number": 10,
      "title": "HELLP syndrome - Symptoms, diagnosis and treatment | BMJ Best Practice US",
      "detail": "bestpractice.bmj.com",
      "url": "https://bestpractice.bmj.com/topics/en-us/1000",
      "authors": "bestpractice.bmj.com",
      "host": "bestpractice.bmj.com"
    },
    {
      "number": 11,
      "title": "2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/ ...",
      "detail": "www.ahajournals.org",
      "url": "https://www.ahajournals.org/doi/10.1161/hyp.0000000000000065",
      "authors": "www.ahajournals.org",
      "host": "www.ahajournals.org"
    },
    {
      "number": 12,
      "title": "2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ ...",
      "detail": "www.ahajournals.org",
      "url": "https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356",
      "authors": "www.ahajournals.org",
      "host": "www.ahajournals.org"
    },
    {
      "number": 13,
      "title": "Preeclampsia—Pathophysiology and Clinical Presentations: \nJACC State-of-the-Art Review",
      "detail": "www.jacc.org",
      "url": "https://www.jacc.org/doi/10.1016/j.jacc.2020.08.014",
      "authors": "www.jacc.org",
      "host": "www.jacc.org"
    },
    {
      "number": 14,
      "title": "fact sheet for healthcare providers: emergency use ...",
      "detail": "go.nature.com",
      "url": "https://go.nature.com/3zbxvqg",
      "authors": "go.nature.com",
      "host": "go.nature.com"
    },
    {
      "number": 15,
      "title": "The Prediction of Pre-Eclampsia Using Low Fetal...",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/01445494-202602000-00010",
      "authors": "journals.lww.com",
      "host": "journals.lww.com"
    },
    {
      "number": 16,
      "title": "A review of clinical practice guidelines on the management of preeclampsia and nursing inspiration",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11650664",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    },
    {
      "number": 17,
      "title": "Preeclampsia: Narrative review for clinical use",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10009735",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    },
    {
      "number": 18,
      "title": "Quality and Content Concordance of International Clinical Guidelines on Hypertensive Disorders of Pregnancy Using the AGREE II Instrument: An Updated Systematic Review",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10380410",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    },
    {
      "number": 19,
      "title": "Hypertensive Disorders of Pregnancy: A Systematic Review of International Clinical Practice Guidelines - PMC",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4249974",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov"
    },
    {
      "number": 20,
      "title": "Eclampsia - StatPearls - NCBI Bookshelf",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK554392",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov"
    },
    {
      "number": 21,
      "title": "Postpartum preeclampsia or eclampsia: defining its place ...",
      "detail": "www.ajog.org",
      "url": "https://www.ajog.org/article/S0002-9378(20)31201-1/fulltext",
      "authors": "www.ajog.org",
      "host": "www.ajog.org"
    },
    {
      "number": 22,
      "title": "Hypertension In Pregnancy - StatPearls - NCBI Bookshelf",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK430839",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov"
    },
    {
      "number": 23,
      "title": "Hypertension in pregnancy: diagnosis and management - NCBI Bookshelf",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK546004",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov"
    },
    {
      "number": 24,
      "title": "Preeclampsia - StatPearls - NCBI Bookshelf",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK570611",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov"
    }
  ],
  "editorialNote": "Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.",
  "citations": [
    {
      "number": 1,
      "title": "highlights of prescribing information",
      "detail": "dailymed.nlm.nih.gov",
      "url": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=eaf135b6-e378-4f62-a1e7-db45e23668c7&type=display",
      "authors": "dailymed.nlm.nih.gov",
      "host": "dailymed.nlm.nih.gov",
      "snippet": "Assess renal function more frequently. (8.5, 8.6)  •  Renal Impairment: Higher incidence of adverse reactions related to volume depletion. (8.6)  •  Hepatic Impairment: Avoid use in patients with hepatic impairment. (8.7)                      See 17 for PATIENT COUNSELING INFORMATION and Medication ",
      "score": 0.32126883
    },
    {
      "number": 2,
      "title": "These highlights do not include all the information needed to use Irbesartan and Hydrochlorothiazide safely and effectively. See full prescribing information for Irbesartan and Hydrochlorothiazide.\n \n      \nIrbesartan and Hydrochlorothiazide tablets, for oral use\n \nInitial U.S. Approval: 1997",
      "detail": "dailymed.nlm.nih.gov",
      "url": "https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=89701339-861a-4e54-a3d6-cf84046e54f2&type=display",
      "authors": "dailymed.nlm.nih.gov",
      "host": "dailymed.nlm.nih.gov",
      "snippet": "Renal Impairment\n\nThe usual regimens of therapy with irbesartan and hydrochlorothiazide may be followed as long as the patient's creatinine clearance is >30 mL/min. In patients with more severe renal impairment, loop diuretics are preferred to thiazides, so irbesartan and hydrochlorothiazide is not ",
      "score": 0.22746114
    },
    {
      "number": 3,
      "title": "DailyMed - MAGNESIUM SULFATE IN DEXTROSE- magnesium sulfate heptahydrate injection, solution",
      "detail": "dailymed.nlm.nih.gov",
      "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4876dcd9-5e8f-47ed-af4f-6a4009ccffd1",
      "authors": "dailymed.nlm.nih.gov",
      "host": "dailymed.nlm.nih.gov",
      "snippet": "## 8.4 Pediatric Use\n\nThe safety and effectiveness of Magnesium Sulfate in 5% Dextrose Injection have been established for the prevention of eclampsia in adolescents with preeclampsia and the treatment of seizures and prevention of recurrent seizures in adolescents with eclampsia. Dosing recommendat",
      "score": 0.22738393
    },
    {
      "number": 4,
      "title": "DailyMed - MAGNESIUM SULFATE IN DEXTROSE- magnesium sulfate injection",
      "detail": "dailymed.nlm.nih.gov",
      "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8da9c33f-e3cd-4026-b034-2b964401b346",
      "authors": "dailymed.nlm.nih.gov",
      "host": "dailymed.nlm.nih.gov",
      "snippet": "## 8.4 Pediatric Use\n\nThe safety and effectiveness of Magnesium Sulfate in 5% Dextrose Injection have been established for the prevention of eclampsia in adolescents with preeclampsia and the treatment of seizures and prevention of recurrent seizures in adolescents with eclampsia. Dosing recommendat",
      "score": 0.22324194
    },
    {
      "number": 5,
      "title": "Predictive Value of the sFlt-1:PlGF Ratio in Women with ...",
      "detail": "www.nejm.org",
      "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1414838",
      "authors": "www.nejm.org",
      "host": "www.nejm.org",
      "snippet": "by H Zeisler · 2016 · Cited by 2338 — In PROGNOSIS, a single cutoff point for the sFlt-1:PlGF ratio, independent of the weeks of gestation, was validated for ruling out preeclampsia,",
      "score": 0.28443733
    },
    {
      "number": 6,
      "title": "Pre-eclampsia - Symptoms, diagnosis and treatment | BMJ Best Practice",
      "detail": "bestpractice.bmj.com",
      "url": "https://bestpractice.bmj.com/topics/en-us/326",
      "authors": "bestpractice.bmj.com",
      "host": "bestpractice.bmj.com",
      "snippet": "open menu\n\nWhen viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.\n\n# Pre-eclampsia\n\nEpidemiology\n\nAetiology\n\nCase history\n\nApproach\n\nHistory and exam\n\nInvestigations\n\nDifferentia",
      "score": 0.24907763
    },
    {
      "number": 7,
      "title": "Strengthening global pre-eclampsia diagnosis",
      "detail": "www.thelancet.com",
      "url": "https://www.thelancet.com/journals/lanogw/article/PIIS3050-5038(26)00057-9/abstract",
      "authors": "www.thelancet.com",
      "host": "www.thelancet.com",
      "snippet": "Harnessing these diagnostics could enhance pre-eclampsia detection, support timely intervention, and ultimately reduce preventable deaths among women and babies",
      "score": 0.1940167
    },
    {
      "number": 8,
      "title": "Placental growth factor testing to assess women with ...",
      "detail": "www.thelancet.com",
      "url": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)33212-4/fulltext",
      "authors": "www.thelancet.com",
      "host": "www.thelancet.com",
      "snippet": "by KE Duhig · 2019 · Cited by 432 — Our trial has demonstrated that, with implementation of PlGF-based testing, clinicians make a quicker diagnosis of pre-eclampsia and there is an",
      "score": 0.17899926
    },
    {
      "number": 9,
      "title": "Treatment for Mild Chronic Hypertension during Pregnancy",
      "detail": "www.nejm.org",
      "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa2201295",
      "authors": "www.nejm.org",
      "host": "www.nejm.org",
      "snippet": "| Any preeclampsia — no. (%) | 295 (24.4) | 373 (31.1) | 0.79 (0.69 to 0.89) |\n| Severe hypertension plus proteinuria | 189 (15.7) | 215 (17.9) | 0.87 (0.73 to 1.04) |\n| Eclampsia | 0 | 1 (0.1) | NA |\n| HELLP | 0 | 3 (0.3) | NA |\n| Hypertension plus end-organ dysfunction | 136 (11.3) | 181 (15.1) | ",
      "score": 0.14396851
    },
    {
      "number": 10,
      "title": "HELLP syndrome - Symptoms, diagnosis and treatment | BMJ Best Practice US",
      "detail": "bestpractice.bmj.com",
      "url": "https://bestpractice.bmj.com/topics/en-us/1000",
      "authors": "bestpractice.bmj.com",
      "host": "bestpractice.bmj.com",
      "snippet": "Although delivery is the only treatment that starts recovery, serious manifestations continue into the immediate postpartum period.\n\n### Definition\n\nAlthough HELLP syndrome is considered by many to be a severe form of preeclampsia, it has a different definition, characterized by hemolysis (H), eleva",
      "score": 0.10140263
    },
    {
      "number": 11,
      "title": "2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/ ...",
      "detail": "www.ahajournals.org",
      "url": "https://www.ahajournals.org/doi/10.1161/hyp.0000000000000065",
      "authors": "www.ahajournals.org",
      "host": "www.ahajournals.org",
      "snippet": "Preeclampsia is a potentially dangerous condition for the pregnant woman and fetus, occurring in 3.8% of pregnancies, and preeclampsia and eclampsia account for 9% of maternal deaths in the United States.S10.2.2-15 Preeclampsia is associated with an increased risk of preterm delivery, intrauterine g",
      "score": 0.388665
    },
    {
      "number": 12,
      "title": "2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ ...",
      "detail": "www.ahajournals.org",
      "url": "https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356",
      "authors": "www.ahajournals.org",
      "host": "www.ahajournals.org",
      "snippet": "by Writing Committee Members* · 2025 · Cited by 773 — guideline-directed medical therapy (GDMT) encompasses clinical evaluation, diagnostic testing, and both pharmacological and procedural treatments.",
      "score": 0.054605763
    },
    {
      "number": 13,
      "title": "Preeclampsia—Pathophysiology and Clinical Presentations: \nJACC State-of-the-Art Review",
      "detail": "www.jacc.org",
      "url": "https://www.jacc.org/doi/10.1016/j.jacc.2020.08.014",
      "authors": "www.jacc.org",
      "host": "www.jacc.org",
      "snippet": "## Eclampsia\n\nEclampsia is defined as new-onset tonic-clonic, focal, or multifocal seizures in the setting of HDP in the absence of other causes (3). Although progesterone raises the seizure threshold, estrogen lowers the seizure threshold via down-regulation of gamma aminobutyric acid (8). A Cochra",
      "score": 0.24392194
    },
    {
      "number": 14,
      "title": "fact sheet for healthcare providers: emergency use ...",
      "detail": "go.nature.com",
      "url": "https://go.nature.com/3zbxvqg",
      "authors": "go.nature.com",
      "host": "go.nature.com",
      "snippet": "patient by a state-licensed pharmacist for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) who are at high risk for progression to severe COVID-19, including hospitalization or death, in accordance with the FDA-approved ",
      "score": 0.28572106
    },
    {
      "number": 15,
      "title": "The Prediction of Pre-Eclampsia Using Low Fetal...",
      "detail": "journals.lww.com",
      "url": "https://journals.lww.com/01445494-202602000-00010",
      "authors": "journals.lww.com",
      "host": "journals.lww.com",
      "snippet": "To investigate the association between low fetal fraction (FF) in non-invasive prenatal testing (NIPT) and pregnancy complications or adverse pregnancy outcomes",
      "score": 0.15560412
    },
    {
      "number": 16,
      "title": "A review of clinical practice guidelines on the management of preeclampsia and nursing inspiration",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11650664",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": "##### MgSO 4 use\n\n3.4.1.5\n(17)MgSO 4 is recommended for first-line treatment of eclampsia (all eight guidelines) and prophylaxis against eclampsia (all but ESC) in women with PE and severe hypertension or adverse maternal conditions (High, Strong).(18)Each unit should have a standard protocol for cl",
      "score": 0.6266047
    },
    {
      "number": 17,
      "title": "Preeclampsia: Narrative review for clinical use",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10009735",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": "Eclampsia is defined as the appearance of one or more generalized tonic-clonic seizures not related to other medical conditions in women with hypertensive disorder of pregnancy. There is loss of autoregulation of cerebral blood flow, blood–brain barrier damage, edema and if it is associated with HEL",
      "score": 0.6216563
    },
    {
      "number": 18,
      "title": "Quality and Content Concordance of International Clinical Guidelines on Hypertensive Disorders of Pregnancy Using the AGREE II Instrument: An Updated Systematic Review",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10380410",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": "it can lead to higher risks of future chronic hypertension after pregnancy. Preeclampsia can occur with the sudden development of high blood pressure, which can lead to life-threatening seizures (eclampsia)  for the mother and fetus. In the United States, preeclampsia occurs in 1 in 25 pregnancies ,",
      "score": 0.6083387
    },
    {
      "number": 19,
      "title": "Hypertensive Disorders of Pregnancy: A Systematic Review of International Clinical Practice Guidelines - PMC",
      "detail": "pmc.ncbi.nlm.nih.gov",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC4249974",
      "authors": "pmc.ncbi.nlm.nih.gov",
      "host": "pmc.ncbi.nlm.nih.gov",
      "snippet": "Eclampsia is consistently defined by new onset and otherwise unexplained seizures in the setting of pre-eclampsia (N = 5 CPGs) [NICE, QLD, WHO, ACOG, SOGC]. No guideline defines the widely used term, ‘imminent eclampsia’.\n\n### Prediction (Table S3)\n\nScreening only by clinical risk markers is recomme",
      "score": 0.54594
    },
    {
      "number": 20,
      "title": "Eclampsia - StatPearls - NCBI Bookshelf",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK554392",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov",
      "snippet": "Pharmacists contribute by reviewing and verifying medication dosages, ensuring no dangerous drug interactions, and collaborating with clinicians to adjust treatments. Seamless communication across all healthcare professionals—including nurses, clinicians, pharmacists, and other support staff—is fund",
      "score": 0.37965488
    },
    {
      "number": 21,
      "title": "Postpartum preeclampsia or eclampsia: defining its place ...",
      "detail": "www.ajog.org",
      "url": "https://www.ajog.org/article/S0002-9378(20)31201-1/fulltext",
      "authors": "www.ajog.org",
      "host": "www.ajog.org",
      "snippet": "Whether postpartum PE or eclampsia represents a distinct entity from PE or eclampsia with antepartum onset is unclear and remains a source of debate. In this review, we do not necessarily propose to label it as a separate disease process but will discuss the limited literature surrounding this entit",
      "score": 0.32743222
    },
    {
      "number": 22,
      "title": "Hypertension In Pregnancy - StatPearls - NCBI Bookshelf",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK430839",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov",
      "snippet": "Eclampsia refers to the pre-eclamptic patient who progresses to have generalized tonic-clonic seizures (typically intrapartum through up to 72 hours postpartum) secondary to her untreated/undertreated pre-eclampsia. Eclampsia occurs in approximately 2-3% of women with severe features who are not rec",
      "score": 0.30000725
    },
    {
      "number": 23,
      "title": "Hypertension in pregnancy: diagnosis and management - NCBI Bookshelf",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK546004",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov",
      "snippet": "#### Why the committee made the recommendations\n\nThe committee updated the table from the previous guideline on the management of pregnancy with pre-eclampsia. There was limited evidence on the best place of treatment for women with pre-eclampsia. Because of this, the committee made recommendations ",
      "score": 0.26249477
    },
    {
      "number": 24,
      "title": "Preeclampsia - StatPearls - NCBI Bookshelf",
      "detail": "www.ncbi.nlm.nih.gov",
      "url": "https://www.ncbi.nlm.nih.gov/books/NBK570611",
      "authors": "www.ncbi.nlm.nih.gov",
      "host": "www.ncbi.nlm.nih.gov",
      "snippet": "This activity reviews the clinical presentation, complications, and management of preeclampsia. The course describes the role of the interprofessional team in managing and improving care for affected patients.\n\nObjectives:\n\nAccess free multiple choice questions on this topic.\n\n## Introduction [...] ",
      "score": 0.18768327
    }
  ],
  "publishedAt": "2026-08-20T23:28:36.987822Z",
  "updatedAt": "2026-08-20T23:28:36.987822Z",
  "readingMinutes": 6,
  "slug": "eclampsia"
}